Review



gene set enrichment analysis biocarta signaling pathway signatures  (BioCarta)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    BioCarta gene set enrichment analysis biocarta signaling pathway signatures
    ( A ) Feature availability among the TCGA (orange), WFCCC (purple), and MDACC (blue) cohorts. Feature names are shown at the right. Unavailable features are labeled in gray. ( B ) Pairwise associations among features in the ER module presented in . The yellow box highlights common associations shared by two groups of associations. ( C ) Patient subtyping using the <t>BioCarta</t> <t>signatures</t> (top region) associated with the ER module. These signatures revealed four subtypes: Immune Inert, Neutral, Active, and Responsive. ( D ) Differential treatment responses assessed by Kaplan-Meier survival analysis of the WFCCC cohort, using distant-metastasis-free survival time as the index. Survival curves of the Immune Neutral (top) and Active (bottom) Subtypes under different treatments are presented and labeled with patient numbers and log-rank test p-values. More details are given in the Supplement.
    Gene Set Enrichment Analysis Biocarta Signaling Pathway Signatures, supplied by BioCarta, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/gene+set+enrichment+analysis+biocarta+signaling+pathway+signatures/gene+set+enrichment+analysis+biocarta+signaling+pathway+signatures/pmc04947904-157-15-15
    Average 90 stars, based on 1 article reviews
    gene set enrichment analysis biocarta signaling pathway signatures - by Bioz Stars, 2026-09
    90/100 stars

    Images

    1) Product Images from "Relational Network for Knowledge Discovery through Heterogeneous Biomedical and Clinical Features"

    Article Title: Relational Network for Knowledge Discovery through Heterogeneous Biomedical and Clinical Features

    Journal: Scientific Reports

    doi: 10.1038/srep29915

    ( A ) Feature availability among the TCGA (orange), WFCCC (purple), and MDACC (blue) cohorts. Feature names are shown at the right. Unavailable features are labeled in gray. ( B ) Pairwise associations among features in the ER module presented in . The yellow box highlights common associations shared by two groups of associations. ( C ) Patient subtyping using the BioCarta signatures (top region) associated with the ER module. These signatures revealed four subtypes: Immune Inert, Neutral, Active, and Responsive. ( D ) Differential treatment responses assessed by Kaplan-Meier survival analysis of the WFCCC cohort, using distant-metastasis-free survival time as the index. Survival curves of the Immune Neutral (top) and Active (bottom) Subtypes under different treatments are presented and labeled with patient numbers and log-rank test p-values. More details are given in the Supplement.
    Figure Legend Snippet: ( A ) Feature availability among the TCGA (orange), WFCCC (purple), and MDACC (blue) cohorts. Feature names are shown at the right. Unavailable features are labeled in gray. ( B ) Pairwise associations among features in the ER module presented in . The yellow box highlights common associations shared by two groups of associations. ( C ) Patient subtyping using the BioCarta signatures (top region) associated with the ER module. These signatures revealed four subtypes: Immune Inert, Neutral, Active, and Responsive. ( D ) Differential treatment responses assessed by Kaplan-Meier survival analysis of the WFCCC cohort, using distant-metastasis-free survival time as the index. Survival curves of the Immune Neutral (top) and Active (bottom) Subtypes under different treatments are presented and labeled with patient numbers and log-rank test p-values. More details are given in the Supplement.

    Techniques Used: Labeling

    Related Articles

    Labeling:

    Article Title: Relational Network for Knowledge Discovery through Heterogeneous Biomedical and Clinical Features
    Article Snippet: The underlying mechanisms of the discovered modules were revealed by gene set enrichment analysis using BioCarta signaling pathway signatures .



    Similar Products

    gene set enrichment analysis biocarta signaling pathway signatures  (BioCarta)
    90
    BioCarta gene set enrichment analysis biocarta signaling pathway signatures
    ( A ) Feature availability among the TCGA (orange), WFCCC (purple), and MDACC (blue) cohorts. Feature names are shown at the right. Unavailable features are labeled in gray. ( B ) Pairwise associations among features in the ER module presented in . The yellow box highlights common associations shared by two groups of associations. ( C ) Patient subtyping using the <t>BioCarta</t> <t>signatures</t> (top region) associated with the ER module. These signatures revealed four subtypes: Immune Inert, Neutral, Active, and Responsive. ( D ) Differential treatment responses assessed by Kaplan-Meier survival analysis of the WFCCC cohort, using distant-metastasis-free survival time as the index. Survival curves of the Immune Neutral (top) and Active (bottom) Subtypes under different treatments are presented and labeled with patient numbers and log-rank test p-values. More details are given in the Supplement.
    Gene Set Enrichment Analysis Biocarta Signaling Pathway Signatures, supplied by BioCarta, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/gene+set+enrichment+analysis+biocarta+signaling+pathway+signatures/gene+set+enrichment+analysis+biocarta+signaling+pathway+signatures/pmc04947904-157-15-15
    Average 90 stars, based on 1 article reviews
    gene set enrichment analysis biocarta signaling pathway signatures - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    ( A ) Feature availability among the TCGA (orange), WFCCC (purple), and MDACC (blue) cohorts. Feature names are shown at the right. Unavailable features are labeled in gray. ( B ) Pairwise associations among features in the ER module presented in . The yellow box highlights common associations shared by two groups of associations. ( C ) Patient subtyping using the BioCarta signatures (top region) associated with the ER module. These signatures revealed four subtypes: Immune Inert, Neutral, Active, and Responsive. ( D ) Differential treatment responses assessed by Kaplan-Meier survival analysis of the WFCCC cohort, using distant-metastasis-free survival time as the index. Survival curves of the Immune Neutral (top) and Active (bottom) Subtypes under different treatments are presented and labeled with patient numbers and log-rank test p-values. More details are given in the Supplement.

    Journal: Scientific Reports

    Article Title: Relational Network for Knowledge Discovery through Heterogeneous Biomedical and Clinical Features

    doi: 10.1038/srep29915

    Figure Lengend Snippet: ( A ) Feature availability among the TCGA (orange), WFCCC (purple), and MDACC (blue) cohorts. Feature names are shown at the right. Unavailable features are labeled in gray. ( B ) Pairwise associations among features in the ER module presented in . The yellow box highlights common associations shared by two groups of associations. ( C ) Patient subtyping using the BioCarta signatures (top region) associated with the ER module. These signatures revealed four subtypes: Immune Inert, Neutral, Active, and Responsive. ( D ) Differential treatment responses assessed by Kaplan-Meier survival analysis of the WFCCC cohort, using distant-metastasis-free survival time as the index. Survival curves of the Immune Neutral (top) and Active (bottom) Subtypes under different treatments are presented and labeled with patient numbers and log-rank test p-values. More details are given in the Supplement.

    Article Snippet: The underlying mechanisms of the discovered modules were revealed by gene set enrichment analysis using BioCarta signaling pathway signatures .

    Techniques: Labeling